11 October 2022
PharmEasy has been pushing its mother brand through the media and raising awareness of its diagnostics vertical (TV, newspapers, OOH, etc.). According to our estimation, Thyrocare's net diagnostics income is already annualizing at more than Rs 1 billion with the help of these marketing inputs and app promotions. As PharmEasy represented tiny sales for Thyrocare at the time of acquisition, those revenues have since climbed to 8% in the fourth quarter of FY22 and 13% in the first quarter of FY23, indicating a quick growth trend.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.